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Summary
Purpose: To provide evidence for the therapeutic efficacy of
oxaliplatin (Eloxatin®) when given as a 2-6-hour i.v. infusion,
alone or in combination with 5-fluorouracil/folinic acid (5-
FU ± FA) in patients with advanced colorectal carcinoma
(ACRC) who have failed 5-FU-based therapy. To confirm the
safety of the drug and its combination in an extended-access
context.
Patients and methods: Prescribing physicians were supplied
oxaliplatin on a nominative compassionate-use basis, after
obtaining informed consent. Europe-wide, 206 ACRC patients
in 44 centers received 1168 cycles of chemotherapy with oxali-
platin (80-100 mg/m2 q 2 weeks or 100-135 mg/m2 q 3 weeks)
delivered as a short (2-6 hours) i.v. infusion, 177 of them (1026
cycles) receiving oxaliplatin + 5-FU ± FA.
Results: Oxaliplatin added to the 5-FU ± FA regimens of
111 verified 5-FU-refractory patients (imaging and/or clinical
proof of progression under prior 5-FU-based regimen), elicited
objective responses in 25 of 98 evaluable patients, (ORR:
25.5%, 95% confidence interval (95% CI: 17-35). The median
time to progression was 4.1 months (95% CI: 3.3-5.0) and
the median overall survival was 9.6 months (95% CI: 8.2-
10.9). Differences in the toxicity profile of the oxaliplatin +
5-FU ± FA combination appear related to administration mo-
dality, dose and schedule of the 5-FU-based regimen.
Conclusions: The addition of oxaliplatin (2-6-hour i.v.
infusion) to 5-FU ± FA regimens is active in ACRC patients
with clinical resistance to fluoropyrimidines. The therapeutic
index of oxaliplatin + 5-FU ± FA combinations administered
as salvage therapy compares favorably with those reported in
recent phase II—III trials involving other new agents or combi-
nations active in 5-FU-refractory ACRC patients.
Key words: 5-fluorouracil, efficacy, oxaliplatin, platinum com-
pounds, salvage chemotherapy
Introduction
Despite the investigation of a variety of 5-FU-based
regimens, the superiority of any particular one has not
yet been established. In first-line treatment for ACRC,
both high-dose and continuous-infusion chemotherapy
are more active than lower dose or bolus 5-FU regimens
but have marginal impact on patient survival [1-3].
Recent 'hybrid' regimens seem to be more active than
the standard regimens in terms of response and time to
progression (TTP) [4-7]. The likelihood of response to a
new 5-FU-based treatment has been linked to the clinical
resistance status observed during prior 5-FU chemo-
therapy; only patients with primary objective response
or disease stabilization are likely to benefit from second-
line 5-FU regimens [8-10].
Oxaliplatin (Eloxatin®, Sanofi-Synthelabo, France) is
a diaminocyclohexane (DACH) platinum compound
with a spectrum of activity and toxicity different from
cisplatin and carboplatin [11]. Preclinical experiments
have shown that oxaliplatin has synergistic cytotoxic
effects when combined with 5-FU [12, 13]. In the past
decade, the oxaliplatin + 5-FU ± FA combination has
been explored extensively in the treatment of 5-FU-pre-
treated ACRC patients. In all such studies, significant
antitumor activity has been observed, with objective
response rates (ORRs) consistently higher than 20%
[14-17]. In these studies, median TTP has been between
6 and 10 months and median overall survival (OS)
between 10 and 17 months, with a significant number of
patients (20%) living more than 2 years.
Following these reports, treating physicians submitted
many individual requests for oxaliplatin as early as 1993.
At that time, most available published data concerning
the treatment of ACRC patients with oxaliplatin were
based on its continuous 4-5-day administration, either
chronomodulated or given as a flat infusion [14]. Simul-
taneously, the French Agence du medicament requested
supplementary evidence of safety and efficacy for oxali-
platin at the recommended administration modality and
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schedule (2-6-hour i.v. infusion every 3 weeks). Due to
the perception of potential benefit for the ACRC patient
population, a nominative, compassionate-use program
had been implemented for the treatment of ACRC
patients failing 5-FU-based therapy. This analysis de-
scribes results from the European-wide ACRC compas-
sionate-use patient cohort treated with short i.v. infu-
sion oxaliplatin + 5-FU ± FA, focusing in particular on
the antitumor activity of the combination in patients
with third-party-reviewed disease progression under a
5-FU-based therapy (5-FU-refractory).
Patients and methods
Cohort definition
Between January 1994 and June 1995, a total of 234 ACRC patients
were registered to receive oxaliplatin as a 2-6-hour i.v. infusion,
excluding chronomodulated and flat continuous i.v. delivery, as salvage
therapy in a European compassionate-use program. The patients were
enrolled in 44 centers on the basis of individual nominative requests
made by their treating physicians.
No restrictions in terms of age, performance status and number or
type of previous treatments were applied. All cases were reviewed
on-site for consistency and compliance with program guidelines, and
all clinical and imaging evidence of resistance to previous 5-FU treat-
ment was reviewed by a team of oncologists and radiologists. Clinical
5-FU refractory status was accorded only when there was third party
verified clinical and/or imaging proof of disease progression while on
the prior 5-FU-based therapy, or a relapse within six months of
completing 5-FU-based adjuvant treatment.
Treatment and patient subgroups
Oxaliplatin was given as a 2-6-hour i.v. infusion in different dose/
schedule combinations, either biweekly at 80-100 mg/m2 or triweekly
at 100-135 mg/m2. Although some patients received oxaliplatin alone
(29 patients, categorized as subgroup A and not included in this
analysis), the majority of patients received oxaliplatin in combination
with a 5-FU ± FA regimen, in which case the oxaliplatin was always
administered first.
Patients who received oxaliplatin + 5-FU ± FA but were not verified
and/or verifiable for clinical resistance to 5-FU, those with inadequate
or inappropriate oxaliplatin dose/schedule, and diagnostically doubt-
ful cases were excluded from the efficacy results but included in the
safety analysis (subgroup D).
The subpopulation of confirmed 5-FU-refractory patients receiv-
ing oxaliplatin + 5-FU ± FA was divided into two categories for
analysis, one consisting of patients receiving oxaliplatin at a dose > 80
mg/m2 q 2 weeks (subgroup B). and another receiving oxaliplatin at a
dose > 100 mg/m2 q 3 weeks (subgroup C).
The 5-FU-refractory patients were further subdivided according to
their 5-FU/FA dose and schedule, with patients receiving an un-
changed schedule placed in subgroups B+ and C+ and those receiving
a modified regimen with respect to their treatment prior to the intro-
duction of oxaliplatin placed in subgroups B- and C-.
The duration of the treatment was determined by the treating
physician, who was responsible for the prescription and for adhesion
to the proposed treatment guidelines.
Safety analysis
All patients receiving at least one cycle of oxaliplatin were evaluable
for safety. Toxic effects were assessed according to WHO criteria [18],
except for neurological toxicity which was graded according to an
oxaliplatin-specific scale [19].
Response analysis
To be eligible for the tumor-response assessment, 5-FU-refractory
patients had to have adequately documented measurable and /or
evaluable disease and had to have received at least two treatment
cycles, except in case of early clinical disease progression.
Evidence of clinical objective response, or disease stabilization ^4
months, and proof of disease progression under the prior 5-FU-based
regimen reported by the participating physicians for all patients allo-
cated to subgroups B or C were submitted to an external panel of
radiologists for review and validation.
As the timing of assessments was at the discretion of the participat-
ing physicians, responses were reported according to modified WHO
criteria [18] (modifications in italics):
• Complete response (CR): complete disappearance of all evi-
dence of tumor assessed in at least two separate evaluations,
one month or more apart.
• Partial response (PR): a > 50% decrease in the sum of products
of the two largest perpendicular diameters of all measurable
lesions and no increase in size of tumor or appearance of any
new lesion.
Patients defined as having CR or PR with only one set of imaging
tests were maintained in the same response category in the absence of
any clinical or biological signs of progression for at least 8 weeks.
• Disease stabilization (SD): < 50% decrease of measurable dis-
ease and ^ 25% progression of measurable disease lasting for at
least four months, without clinical, biological or imaging evidence
of disease progression, and no evidence of any new lesion.
• Progressive disease (PD): >25% increase in the sum of the
products of two diameters of one or more measurable lesions,
evidence of new lesions, death from disease progression within
eight weeks after the first administration of oxaliplatin, or lack
of formal disease evaluation after three cycles of treatment.
Time-related parameters
Follow-up information to determine TTP and OS were collected for
the 5-FU-refractory patients. TTP and OS were calculated from the
beginning of the treatment containing oxaliplatin until either disease
progression or death, respectively.
Statistical analysis
A descriptive analysis of disease and patient characteristics, previous
therapy, oxaliplatin treatment schedule, time-related parameters, re-
sponse, and toxicity was carried out (mean, median, standard devia-
tion, 95% confidence interval (95% CI), and range of values) using
the STATISTICA system (STAT SOFT, Tulsa, OK, USA). Response
rate was characterized using descriptive statistics (mean, median,
standard deviation, 95% CI, and range of values) and the Pearson
X2 test for univariate analysis. TTP and OS were analyzed according
to the Kaplan-Meier method and log-rank test for univariate anal-
ysis.
Results
Cohort characteristics
After source verification, 206 out of the 234 registered
ACRC patients were considered eligible for analysis,
with 28 failing to fulfill the accrual guidelines or missing
the deadline for inclusion. Out of these 206 patients, 29
had received single-agent oxaliplatin. Of the remaining
177, all of whom received oxaliplatin + 5-FU ± FA, 111
(63%) were source verified as being 5-FU refractory.
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Table I. Patient and disease characteristics.
Characteristics
Sex
Male
Female
PS (WHO)
0-1
2-3
Primary tumor
Colon
Rectum
Number of metastatic
sites
1
2
s=3
Metastatic sites
Liver
Lung
Lymph nodes
Peritoneum
Bone
Others
Elevated markers8
CEA
CA19 9
Prior surgery
Prior radiotherapy
Prior chemotherapy
Adjuvant
Palliative
Number of prior
chemotherapy regimens
1
2
3=3
Prior cisplatin-CBDCA
Treatment-free interval
^ 2 months
^ 3 months
^ 6 months
6 months
Subgroups of 5-FU-refractory patient
B+
(" = 33)
15
18
27
6
25
8
17
8
8
31
8
7
3
2
2
23
15
33
7
33
5
28
23
4
6
2
30
0
2
1
B -
(n = 16
7
9
12
4
8
8
5
6
5
13
5
5
3
1
1
9
9
16
4
16
6
10
6
4
6
2
10
2
4
0
C+
|) d=35)
25
10
32
3
18
17
19
12
4
27
16
6
1
0
0
25
17
35
12
35
4
31
20
10
5
1
26
5
4
0
C -
(n=27)
11
16
21
6
18
9
7
5
15
22
14
13
7
2
6
20
18
27
8
27
8
19
10
8
9
2
17
5
4
1
Total
(n = lli;
58
53
92
19
69
42
48
31
32
93
43
31
14
5
9
77
59
111
31
111
23
88
59
26
26
7
83
12
14
2
Per-
) centage
52
48
83
17
62
38
43
28
29
84
39
28
13
5
8
69
53
100
28
100
21
79
53
23
23
6
75
11
13
2
B, verified 5-FU-refractory patients receiving oxaliplatin q 2 weeks + 5-FU ± FA
regimen; C, the same as B, except receiving oxaliplatin q 3 weeks, B+. C+, prior
5-FU ± FA regimen unmodified: B- , C - , prior 5-FU ± FA regimen modified.
J
 > 2x upper normal limit.
Patient and disease and prior treatment characteristics
at inclusion are listed in Table 1.
The 5-FU-refractory population included 58 men
and 53 women. Most of these patients had good perfor-
mance status (PS), with 83% reporting a WHO grade 0
or 1 PS, and 63 (57%) had 2 or more sites involved.
Twenty-three of the 5-FU-refractory patients (21%)
had received prior chemotherapy in the adjuvant setting.
When the pre-oxaliplatin treatments were considered,
eight different main modalities of 5-FU ± FA doses/
schedules were identified, with the three most common
modalities being daily (x 4-5 days) or weekly bolus or
continuous infusion, biweekly bolus and/or continuous
infusion, and protracted infusion.
Eighty-three 5-FU-refractory patients (75%) had re-
ceived their last chemotherapy within two months of the
first oxaliplatin dose.
Safety
A total of 1026 oxaliplatin-containing treatment cycles
were administered in combination with 5-FU ± FA to
177 patients. A total cumulative dose of > 520 mg/m2
oxaliplatin was given to 94 of 177 patients (53%). One
hundred twenty-two patients (69%) received between
four and nine cycles. Toxicities are presented in Table 2
by patient and by cycle.
The most common adverse events amongst the patients
receiving the combination treatment were mucositis, diar-
rhea and hematological toxicities. Diarrhea was the most
frequent acute toxicity, severe episodes being observed
in 28% of patients and 8% of cycles. Severe (grade 3-4)
nausea/vomiting was reported in 17% of patients but
only 3% of cycles were associated with grade 3-4 tox-
icity. Severe (grade 3-4) neutropenia and thrombocyto-
penia were uncommon, being observed in only 10% and
7% of patients or 5% and 1.6% of cycles, respectively.
Eighty-two percent of patients receiving oxaliplatin +
5-FU ± FA reported some signs and/or symptoms of
neuropathy. Characteristic oxaliplatin-related neuro-
toxicity may occur early in treatment, presenting as
transient acute, cold-triggered dysesthesias, and/or later,
as a cumulative toxicity characterized by proprioceptive
impairment [20]. Overall, 29 patients (18%) reported
neurological grade 3-4 toxicity (old version of oxalipla-
tin-specific grading scale), with only 6 (3%) reporting a
grade 4 toxicity (persistent functional impairment, usu-
ally minor and slowly reversible upon treatment discon-
tinuation). The incidence of severe neurotoxicity was
correlated with the cumulative oxaliplatin dose.
No renal or ototoxicity was reported. The three
deaths that occurred within a month of the last oxali-
platin + 5-FU ± FA combination chemotherapy were all
from characteristic 5-FU-related toxic effects.
Antitumor activity
Out of 111 verified 5-FU-refractory patients, 98 were
found to be assessable for objective anti-tumor activity.
Reasons for non-evaluability were: inadequate assess-
ment documentation or disease considered not measur-
able/evaluable, patient refusal, and early treatment
discontinuation. Responses achieved for the subgroups
of 5-FU-refractory patients are detailed in Table 3.
Overall, there were 25 objective responses and 31
disease stabilizations >4 months among the 5-FU-re-
fractory patients treated with oxaliplatin + 5-FU ± FA,
giving an ORR of 25.5% (95% CI: 17%-35%).
With each patient acting as his or her own control
(addition of oxaliplatin to unchanged 5-FU ± FA regi-
men), evidence for the contribution of oxaliplatin to the
antitumor activity of the combined salvage regimen is
provided by the results for the B+ (ORR: 32%) and C+
(ORR: 31%). No substantial difference in response rate
was observed between the subgroups of patients who
received oxaliplatin every two weeks (B) vs. every three
weeks (C) (26.7% vs. 24.5%, respectively).
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Table 2. Toxicity by patient and cycle.
Toxicity
Gastrointestinal"
Nausea/vomiting
Mucositis
Diarrhea
Hematological"
Leukopenia
Neutropenia
Thrombopenia
Anemia
Peripheral neurotoxicityb
Oxaliplatin + 5-FU ± FA
n = 177 patients
Evaluable
patients
168
166
166
168
166
167
167
165
Grades 1-4
(%)
115(68)
57 (34)
111 (67)
92 (55)
91 (55)
57 (34)
81 (48)
136(82)
Grades 3-4
(%)
27(16)
10(6)
47 (28)
17(9)
34(10)
12(7)
6(4)
29(18)
n = 1026 cycles
Evaluable cycles
922
923
923
940
923
936
939
920
Grades 1-4
(%)
328 (36)
153(17)
294 (32)
261 (28)
245 (26)
144(15)
245 (26)
653(71)
Grades 3-4
(%)
31(3)
13(1)
72(8)
22(2)
48(5)
15(2)
8(1)
49(5)
WHO criteria.
' Oxaliplatin-specific scale [19].
Table 3. Response to treatment.
Patient
sub-
group
B+
B -
C+
c-
B & C
Oxaliplatin +
5-FU + FA treatment
regimen
q 2 wk(unchanged
5-FU ± FA schedule)
q 2 wk (modified
5-FU ± FA schedule)
q 3 wk (unchanged
5-FU ± FA schedule)
q 3 wk (modified
5-FU ± FA schedule)
All 5-FU-refractory
patients
Number
treated/
evaluable
33/31
16/14
35/29
27/24
111/98
Antitumor response
CR
1
0
0
0
1
PR
9
2
9
4
24
SD
7
6
4
12
29
PD
14
6
16
8
44
Response rate
(95% CI)
32% (17-51)
14%(2^t3)
31% (15-51)
17% (5-37)
25.5% (17-35)
TTP in months
(95% CI)
5.7 (4.8-6.6)
3.2(1.4-5.0)
3.5 (2.2-4.8)
4.5(3.8-5.2)
4.1(3.2-5.0)
Survival in
months
(95% CI)
10.4(7.7-73.1)
10.6(4.3-16.9)
7 7(1.4-14.1)
6.9 (4.7-9.0)
9.6(8.2-10.9)
Abbreviations: CR - complete response; PR - partial response; SD - stable disease; PD - progressive disease; TTP - time to disease
progression; CI - confidence interval.
In multivariable analysis, performance status and
previous number of chemotherapy regimens were the
only two variables to show statistical significance
(P < 0.004 and P < 0.03, respectively) for their inde-
pendent predictive value of response likelihood in the
5-FU-refractory patients.
Time-related parameters
The 5-FU-refractory patients were assessed for TTP and
OS, with follow-up until December 1996 (17-18 months
after the accrual of the last patient). The median TTP
and OS for the 111 5-FU-refractory patients in sub-
groups B and C were 4.1 months (95% CI: 3.3-5.0) and
9.6 months (95% CI: 8.2-10.9), respectively. Both pa-
rameters were higher for the patients treated with a
biweekly administration schedule for the oxaliplatin
than with the 3-week schedule (category B vs. category
C; TTP: 5.4 vs. 4.0 months and OS: 10.6 vs. 7.7 months),
although this difference was not statistically significant.
Discussion
This analysis provides further evidence for the efficacy
and safety of oxaliplatin when added to a 5-FU ± FA
treatment for metastatic/recurrent colorectal cancer pa-
tients, notably in patients verified as 5-FU refractory.
These results were obtained in a large, heterogeneous
cohort of patients receiving oxaliplatin in a compas-
sionate-use program, rather than in a clinical trial. This
analysis gives valuable information because the attribu-
tion of drug therapy in a compassionate-use framework
is less selective than in phase II—III studies, and patients
entering such a program have clinical, treatment and
disease characteristics closely reflecting those encoun-
tered in everyday practice. The characteristics of the
present cohort attest to the lack of patient selection for
oxaliplatin treatment in this program. Numerous 5-FU
regimens were administered, either unchanged or modi-
fied with respect to those given prior to the addition of
oxaliplatin. Such diversity allowed us to assess the con-
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tribution of oxaliplatin in the context of different 5-FU
treatment regimens. The analysis was intended to examine
the efficacy of oxaliplatin and to determine its contribu-
tion to any observed antitumor activity in this heteroge-
neous patient cohort with more precision.
This study supports the view that oxaliplatin is both
active and exhibits synergistic antitumor activity with
5-FU in 5-FU-refractory ACRC patients. This observa-
tion is consistent with previously reported phase II
experiences [14, 16, 17, 21, 22]. We applied strict criteria
to define resistance to prior treatment including verified,
documented evidence of disease progression while on
5-FU ± FA treatment. In many studies the assessment of
such status has either not been provided or else the
guidelines for defining it have been less strict or unspe-
cified [23]. All clinical and radiological charts of patients
allocated to the 5-FU refractory categories (B and C)
were reviewed by independent external experts. Under
such conditions, the efficacy data reported in patients
with 5-FU-refractory disease can be considered a reliable
indicator of oxaliplatin's contribution to efficacy. The
response rate of 25.5%, the median TTP of 4.1 months,
and the median OS of 9.6 months calculated for the
patients in groups B and C are within the range of those
reported in formal phase II—III trials. Oxaliplatin activity
was also consistently noted whatever 5-FU ± FA regimen
it was combined with, including the weekly, biweekly
and triweekly schedules, as well as bolus and infusional
administration.
The safety profile of oxaliplatin given alone or com-
bined with 5-FU ± FA presented here is consistent with
previously reported data [14, 22, 24-26]. A higher fre-
quency of diarrhea, mucositis, and neutropenia was
reported when combined with 5-FU ± FA. In this heter-
ogeneous patient cohort, oxaliplatin was combined in
the majority of cases with high-dose-intensity 5-FU ± FA
regimens. Accordingly, we noted more severe hematotox-
icity and diarrhea when compared to other oxaliplatin +
5-FU ± FA experiences [14, 21]. Although peripheral
neuropathy is the limiting toxicity for oxaliplatin, the
most frequent neurological manifestations observed
were grades 1 or 2 (transient dysesthesias and/or pares-
thesias). Clinical experience has shown that laryngo-
pharyngeal dysesthesias are more frequent when the
drug is given in a short (two-hour) infusion; prolonging
the infusion (^6 hours) in such cases can prevent the
recurrence of this adverse event. In the present popula-
tion, grade 4 neurotoxic effects (persistent paresthesia
causing functional impairment) occurred in 3% of pa-
tients. This sensory neuropathy was clearly related to the
cumulative oxaliplatin dose and is consistent with those
previously observed [27]. Overall, oxaliplatin can safely
be given at the recommended dose and schedule in
combination with a wide variety of 5-FU ± FA regimens.
Finally, our results failed to elicit any evidence that
the synergistic activity of oxaliplatin when used in com-
bination with 5-FU ± FA is dependent on the modality
of administration, dose or schedule of the 5-FU-con-
taining regimen.
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